))
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Manage episode 366778719 series 2838329
المحتوى المقدم من VJHemOnc. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة VJHemOnc أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refractory (R/R) disease. Several clinical trials are evaluating the efficacy of CAR-T cells and are further exploring the possibility of bringing these agents into earlier lines of therapy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Jesús San Miguel, MD, University of Navarra, Pamplona, Spain, and Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, who share some updates from the CARTITUDE-4 and CARTITUDE-1 trials (NCT04181827; NCT03548207), and further comment on current and emerging uses of measurable residual disease (MRD) in clinical practice.
200 حلقات
مشاركة
